In CRC cells, immunotherapy can block the PD-1/PD-L1 axis through the gene level downregulation of PD-L1 expression and could be achieved by small interfering RNAs combined with anti-VEGF-A and anti-PD-1 [139]. Here, VEGFA is linked to colorectal carcinoma.